Genprex Inc. (GNPX)
0.27
0.01 (1.89%)
At close: Apr 11, 2025, 3:59 PM
0.27
0.78%
After-hours: Apr 11, 2025, 05:47 PM EDT
Company Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes.
Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer.
The company is also developing GPX-002, a preclinical stage gene therapy for diabetes.
Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Genprex Inc.
| Country | United States |
| IPO Date | Mar 29, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 19 |
| CEO | Ryan M. Confer M.S. |
Contact Details
Address: 3300 Bee Cave Road Austin, Texas United States | |
| Website | https://www.genprex.com |
Stock Details
| Ticker Symbol | GNPX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001595248 |
| CUSIP Number | 372446104 |
| ISIN Number | US3724462037 |
| Employer ID | 90-0772347 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ryan M. Confer M.S. | President, Chief Executive Officer, Chief Financial Officer & Director |
| David M. Schloss | Senior Vice President of Human Resources |
| Dr. Jack A. Roth F.A.C.S., M.D. | Chairman of Scientific & Medical Advisory Board |
| Dr. Mark S. Berger M.D. | Chief Medical Officer |
| Dr. Suzanne Thornton-Jones Ph.D. | Senior Vice President of Regulatory Affairs & Quality |
| Thomas C. Gallagher Esq. | Senior Vice President of Intellectual Property & Licensing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 01, 2025 | NT 10-K | Filing |
| Apr 01, 2025 | 10-K | Annual Report |
| Feb 19, 2025 | 4 | Filing |
| Feb 19, 2025 | 4 | Filing |
| Feb 18, 2025 | 8-K | Current Report |
| Feb 12, 2025 | 8-K | Current Report |
| Jan 24, 2025 | S-8 | Filing |
| Jan 23, 2025 | 8-K | Current Report |
| Jan 15, 2025 | SCHEDULE 13G | Filing |
| Jan 13, 2025 | 8-K | Current Report |